FDA OKs human trial of RevBio’s bone adhesive biomaterial
RevBio has been given approval from the U.S. Food and Drug Administration (FDA) to start a 20-patient trial to study the safety and efficacy of its bone adhesive biomaterial, Tetranite. The clinical trial will explore a more rapidly replaced, pH-modified porous formulation of the biomaterial, which aims to immediately stabilize dental implants following tooth extractions. This new formulation has shown evidence of a more biologically active bone substitution. While not



